Evidence map›Paper›PMID 29572681›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2019

HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Jonathan Herskovitz, Howard E Gendelman

Abstract readReview
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Mechanisms of Intracellular Communication in Cancer and Pathogen Spreading.Results and problems in cell differentiation · 2024
    Review
  6. Role of Monocyte/Macrophages in the Pathogenesis of NeuroHIV.Results and problems in cell differentiation · 2024
    Review
  7. Article
  8. The role of autophagy in the progression of HIV infected cardiomyopathy.Frontiers in cell and developmental biology · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Macrophage Polarity and Disease Control.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Review
  20. Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).Journal of molecular medicine (Berlin, Germany) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jonathan HerskovitzDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Howard E GendelmanDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. hegendel@unmc.edu.

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
SMART HANDR01AG043540 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, POLUEKTOVA, LARISA Y · 2013 to 2017
$3.1M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
Chemical, Nanomedicine and Autophagy Strategies to Create Sustained-Release Antiretroviral ProductsR56AI138613 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2018 to 2018
$720k
NIAID NIH HHS R56 AI138613NIA NIH HHS R01 AG043540NIDA NIH HHS P01 DA028555NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH115860NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Macrophages serve as host cells, inflammatory disease drivers and drug runners for human immunodeficiency virus infection and treatments. Low-level viral persistence continues in these cells in the absence of macrophage death. However, the cellular microenvironment changes as a consequence of viral infection with aberrant production of pro-inflammatory factors and promotion of oxidative stress. These herald viral spread from macrophages to neighboring CD4

Indexed as

AnimalsDrug Delivery SystemsHIVHIV InfectionsHumansMacrophagesVirus LatencyCell ontogenyHuman immunodeficiency virusLong acting slow effective release antiretroviral therapyMonocyte-derived macrophagesMononuclear phagocytesViral persistenceViral reservoirs

Identifiers

PMID29572681
PMCPMC6501843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.